All In Biotech

Drug Trial Radar · NCT06821503

Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

An Open Label Phase Ib/II Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab Plus Chemotherapy in Patients With Advanced Solid Tumors - Cohort C

Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Apr 11, 2025

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Feb 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is the cohort C part of a multicenter, open label Phase Ib/II clinical study evaluating the preliminary efficacy, safety, and tolerability of LM-108 combined with anti-tumor therapy in patients with advanced solid tumors. The dose of LM-108 combined with penpulimab, albumin paclitaxel, and gemcitabine is recommended in Phase Ib.Explore the efficacy and safety of LM-108 combined with anti-tumor therapy in patients with advanced pancreatic cancer in Phase II.

Conditions

  • Advanced Pancreatic Cancer

Interventions

  • LM-108 injectionDrug

    LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.

  • Penpulimab injectionDrug

    Penpulimab injection is a Programmed Cell Death Protein 1 (PD-1) immune checkpoint inhibitor.

  • Paclitaxel for injection (albumin bound)Drug

    Paclitaxel for injection (albumin bound) is a cytotoxic anticancer drug

  • Gemcitabine hydrochloride for injectionDrug

    Gemcitabine hydrochloride for injection is a cell cycle specific anti-tumor drug that can inhibit the growth of tumor cells and belongs to a type of chemotherapy drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: Baseline up to 28 days
  2. Progression-Free Survival (PFS)Time frame: Up to 48 weeks

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Cancer Hospital Chinese Academy of Medical Science

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing Qeneral Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Huazhong University of Science and Technology Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Not yet recruiting

  • The First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • The Sixth People's Hospital of Shenyang

    Shenyang, Liaoning, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University Medical College

    Xi'an, Shaanxi, China · Not yet recruiting

  • The First Affiliated Hospital of Naval Medical University

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Tianjin Cancer Hospital Airport Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.